Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Xeris Pharmaceuticals (XERS) stock

Learn how to easily invest in Xeris Pharmaceuticals stock.

Xeris Pharmaceuticals, Inc
NASDAQ: XERS - USD
BIOTECHNOLOGY
$3.32
+$0.09 (+2.79%)

Xeris Pharmaceuticals, Inc is a biotechnology business based in the US. Xeris Pharmaceuticals shares (XERS) are listed on the NASDAQ and all prices are listed in US Dollars. Xeris Pharmaceuticals employs 209 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Xeris Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XERS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Xeris Pharmaceuticals stock price (NASDAQ: XERS)

Use our graph to track the performance of XERS stocks over time.

Xeris Pharmaceuticals shares at a glance

Information last updated 2021-07-24.
Latest market close$3.33
52-week range$2.62 - $7.94
50-day moving average $3.95
200-day moving average $4.50
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.11

Buy Xeris Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xeris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xeris Pharmaceuticals price performance over time

Historical closes compared with the close of $3.33 from 2021-05-26

1 week (2021-07-17) N/A
1 month (2021-06-28) -25.67%
3 months (2021-04-28) -17.37%
6 months (2021-01-24) N/A
1 year (2020-07-24) N/A
2 years (2019-07-24) N/A
3 years (2018-07-24) N/A
5 years (2016-07-24) N/A

Xeris Pharmaceuticals financials

Revenue TTM $26.8 million
Gross profit TTM $11.2 million
Return on assets TTM -30.81%
Return on equity TTM -224.94%
Profit margin -299.41%
Book value $0.67
Market capitalisation $223 million

TTM: trailing 12 months

Shorting Xeris Pharmaceuticals shares

There are currently 13.4 million Xeris Pharmaceuticals shares held short by investors – that's known as Xeris Pharmaceuticals's "short interest". This figure is 13.9% down from 15.6 million last month.

There are a few different ways that this level of interest in shorting Xeris Pharmaceuticals shares can be evaluated.

Xeris Pharmaceuticals's "short interest ratio" (SIR)

Xeris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xeris Pharmaceuticals shares currently shorted divided by the average quantity of Xeris Pharmaceuticals shares traded daily (recently around 5.1 million). Xeris Pharmaceuticals's SIR currently stands at 2.64. In other words for every 100,000 Xeris Pharmaceuticals shares traded daily on the market, roughly 2640 shares are currently held short.

However Xeris Pharmaceuticals's short interest can also be evaluated against the total number of Xeris Pharmaceuticals shares, or, against the total number of tradable Xeris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xeris Pharmaceuticals's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Xeris Pharmaceuticals shares in existence, roughly 200 shares are currently held short) or 0.2421% of the tradable shares (for every 100,000 tradable Xeris Pharmaceuticals shares, roughly 242 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xeris Pharmaceuticals.

Find out more about how you can short Xeris Pharmaceuticals stock.

Xeris Pharmaceuticals share dividends

We're not expecting Xeris Pharmaceuticals to pay a dividend over the next 12 months.

Xeris Pharmaceuticals share price volatility

Over the last 12 months, Xeris Pharmaceuticals's shares have ranged in value from as little as $2.62 up to $7.94. A popular way to gauge a stock's volatility is its "beta".

XERS.US volatility(beta: 1.86)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xeris Pharmaceuticals's is 1.8567. This would suggest that Xeris Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Xeris Pharmaceuticals overview

Xeris Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Xeris Pharmaceuticals is owned by insiders or institutions?
Currently 0.984% of Xeris Pharmaceuticals shares are held by insiders and 56.399% by institutions.
How many people work for Xeris Pharmaceuticals?
Latest data suggests 209 work at Xeris Pharmaceuticals.
When does the fiscal year end for Xeris Pharmaceuticals?
Xeris Pharmaceuticals's fiscal year ends in December.
Where is Xeris Pharmaceuticals based?
Xeris Pharmaceuticals's address is: 180 North LaSalle Street, Chicago, IL, United States, 60601
What is Xeris Pharmaceuticals's ISIN number?
Xeris Pharmaceuticals's international securities identification number is: US98422L1070
What is Xeris Pharmaceuticals's CUSIP number?
Xeris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98422L107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site